Innovent Biologics Inc (IVBXF PINK) stock market data APIs
$14.3823
0(0%)
as of August 31, 2026
Try our APIs with
free plan!
Innovent Biologics Inc Financial Data Overview
Price chart is built with
Anychart
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Prev. Close
14.3823
Open
14.3823
High
14.3823
Low
14.3823
52 wk Range
9.1-15.008
Market Cap
24 888 M
P/E Ratio
203.8857
Shares Outstanding
1 744 M
Revenue
15 706 M
Beta
0.228
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Innovent Biologics Inc data using free add-ons & libraries
Get Innovent Biologics Inc Fundamental Data
Innovent Biologics Inc Fundamental data includes:
- Net Revenue: 15 706 M
- EBITDA: 1 703 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-25
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Innovent Biologics Inc News
New
Does Daiichi Sankyo Company (TSE:4568) Have A Bigger Oncology Opening In China And Europe?
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Daiichi Sankyo Company (TSE:4568) has signed an exclusive commercialization agreemen...
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Spero Therapeutics, Inc. Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Dr...
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801....
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializ...
Get Innovent Biologics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
